MED1 and myocardial infarction: Protects the myocardium from IRI by inhibition of NF-kB and TRAF6/p-p38/caspase-3 signaling pathways, targeting SMAD4, EGR1, and MED1; suppresses inflammatory cytokine production via IRAK-1 and TRAF6 [228,229,230,231,232], inhibits mitochondrial dysfunction in myocardial infarction by targeting cyclophilin D [233], regulates VEGF expression in the IRI heart [234].